PEX13 is a potential immunotherapeutic indicator and prognostic biomarker for various tumors including PAAD

被引:1
|
作者
Dong, Penggang [1 ,2 ]
Du, Xuezhi [1 ]
Yang, Ting [3 ]
Li, Dandan [3 ]
Du, Yunyi [4 ]
Wei, Yaqing [1 ]
Sun, Jinjin [1 ,5 ]
机构
[1] Tianjin Med Univ, Hosp 2, Dept Hepatopancreatobiliary Surg, Tianjin 300211, Peoples R China
[2] Changzhi Peoples Hosp, Changzhi Med Coll, Dept Hepatobiliary Surg, Changzhi 046000, Shanxi, Peoples R China
[3] Changzhi Peoples Hosp, Changzhi Med Coll, Cent Lab, Changzhi 046000, Shanxi, Peoples R China
[4] Changzhi Peoples Hosp, Changzhi Med Coll, Dept Oncol, Changzhi 046000, Shanxi, Peoples R China
[5] Tianjin Med Univ, Hosp 2, Dept Hepatopancreatobiliary Surg, 23 Pingjiang Rd, Hexi, Tianjin 300211, Peoples R China
关键词
PEX13; prognosis; immune; PAAD; ncRNA-miRNA-PEX13; network; PEROXISOMES; CANCER; MITOCHONDRIAL; PROTEIN; METABOLISM; HYBRID;
D O I
10.3892/ol.2023.14099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The peroxisome serves a significant role in the occurrence and development of cancers. Specifically, the peroxisomal biogenesis factor 13 (PEX13) is crucial to the occurrence of peroxisomes. However, the biological function of PEX13 in cancers remains unclear. To address this, various portals and databases such as The Cancer Genome Atlas Program, The Genotype-Tissue Expression project, the Gene Expression Profiling Interactive Analysis 2, cBioPortal, the Genomic Identification of Significant Targets In Cancer 2.0, Tumor Immune Estimation Resource 2, SangerBox, LinkedOmics, DAVID and STRING were applied to extract and analyze PEX13 data in tumors. The correlations between PEX13 and prognosis, genetic alterations, PEX13-related gene enrichment analysis, weighted gene co-expression network analysis (WGCNA), protein interaction, long non-coding (lnc)RNA/circular (circ)RNA-micro (mi)RNA network and tumor immunity were explored in various tumors. The lncRNA-miRNA-PEX13 and circRNA-miRNA-PEX13 regulatory networks were identified via miRabel, miRDB, TargetScan and ENCORI portals and Cytoscape tool. In vitro assays were applied to verify the biological functions of PEX13 in pancreatic adenocarcinoma (PAAD) cells. The findings revealed that PEX13 is upregulated in various tumors and high PEX13 mRNA expression is associated with poor prognosis in patients with multiple cancers. Genetic alterations in PEX13 such as amplification, mutation and deep deletion have been found in multiple cancers. PEX13-related genes were associated with T cell receptor, signaling pathway and hippo signaling pathway through 'biological process' subontology of Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Through WGCNA analysis, it was discovered that PEX13 hub genes were mainly enriched in the Rap1, ErbB and AMPK signaling pathways in PAAD. Immune analysis showed that PEX13 was significantly related to tumor infiltration immune cells, immune checkpoint genes, microsatellite instability, TMB and tumor purity in a variety of tumors. Cell Counting Kit-8, wound healing, Transwell and colony formation assays displayed that PEX13 knockdown could suppress PAAD cell proliferation, migration, invasion, and colony formation in vitro, respectively. Overall, PEX13 is a potential predictor of immunotherapeutic and prognostic biomarkers in various malignant tumors, including ACC, KICH, LGG, LIHC and PAAD.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2
    Wu, Xiaocong
    Chen, Hui
    You, Chao
    Peng, Zongjun
    HEREDITAS, 2023, 160 (01)
  • [2] A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2
    Xiaocong Wu
    Hui Chen
    Chao You
    Zongjun Peng
    Hereditas, 160
  • [3] GTSE1: A potential prognostic and diagnostic biomarker in various tumors including lung adenocarcinoma
    Yan, Guanqiang
    Li, Guosheng
    Gao, Xiang
    Liu, Jun
    Li, Yue
    Li, Jingxiao
    Zhou, Huafu
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [4] Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma
    Pan, Boyu
    Cheng, Xiaoyun
    Tan, Wei
    Liu, Renfeng
    Wu, Xin
    He, Jinpeng
    Fan, Qizhi
    Zhang, Yan
    Cheng, Jun
    Deng, Youwen
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [5] MMP12 is a Potential Predictive and Prognostic Biomarker of Various Cancers Including Lung Adenocarcinoma
    Li, Guo-Sheng
    Tang, Yu-Xing
    Zhang, Wei
    Li, Jian-Di
    Huang, He-Qing
    Liu, Jun
    Fu, Zong-Wang
    He, Rong-Quan
    Kong, Jin-Liang
    Zhou, Hua-Fu
    Chen, Gang
    CANCER CONTROL, 2024, 31
  • [6] Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas (vol 13, 849592, 2022)
    Wei, Cheng
    Wang, Bo
    Peng, Dazhao
    Zhang, Xiaoyang
    Li, Zesheng
    Luo, Lin
    He, Yingjie
    Liang, Hao
    Du, Xuezhi
    Li, Shenghui
    Zhang, Shu
    Zhang, Zhenyu
    Han, Lei
    Zhang, Jianning
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] Long noncoding RNA SNHG12 is a potential diagnostic and prognostic biomarker in various tumors
    Wang X.
    Jiang Q.
    Zhang C.
    Yang Q.
    Wang L.
    Zhang J.
    Wang L.
    Chen X.
    Hou X.
    Han D.
    Wu J.
    Zhao S.
    Chinese Neurosurgical Journal, 7 (1)
  • [8] TIPARP as a prognostic biomarker and potential immunotherapeutic target in male papillary thyroid carcinoma
    Zhang, Jianlin
    Zhou, Xumin
    Yao, Fan
    Zhang, Jiali
    Li, Qiang
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [9] TIPARP as a prognostic biomarker and potential immunotherapeutic target in male papillary thyroid carcinoma
    Jianlin Zhang
    Xumin Zhou
    Fan Yao
    JiaLi Zhang
    Qiang Li
    Cancer Cell International, 24
  • [10] MAGE-A11 is a potential prognostic biomarker and immunotherapeutic target in gastric cancer
    Wang, Zhi-Wen
    Yu, Qi-Ying
    Xu, Meng-Jiao
    Zhou, Chuan-Yi
    Li, Jia-Peng
    Liao, Xing-Hua
    AGING-US, 2024, 16 (01): : 285 - 298